Maribavir: First Approval

被引：30

作者：

Kang, Connie ^{[1
]}

机构：

[1] Springer Nat, Private Bag 65901, Auckland 0754, New Zealand

来源：

DRUGS | 2022年 / 82卷 / 03期

关键词：

DOUBLE-BLIND; CYTOMEGALOVIRUS DISEASE; TRANSPLANT RECIPIENTS; PREVENTION; PROPHYLAXIS; MULTICENTER;

D O I：

10.1007/s40265-022-01677-4

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Maribavir (LIVTENCITYTM), a cytomegalovirus (CMV) enzyme pUL97 kinase inhibitor, is being developed by Takeda Pharmaceuticals for the treatment of CMV infections. Maribavir was recently approved in the USA for the treatment of post-transplant CMV infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet in adults and paediatric (>= 12 years of age and weighing >= 35 kg) patients. This article summarizes the milestones in the development of maribavir leading to this first approval for CMV infections.

引用

页码：335 / 340

页数：6

共 13 条

[1] Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial [J].

Avery, Robin K. ;

Alain, Sophie ;

Alexander, Barbara D. ;

Blumberg, Emily A. ;

Chemaly, Roy F. ;

Cordonnier, Catherine ;

Duarte, Rafael F. ;

Florescu, Diana F. ;

Kamar, Nassim ;

Kumar, Deepali ;

Maertens, Johan ;

Marty, Francisco M. ;

Papanicolaou, Genovefa A. ;

Silveira, Fernanda P. ;

Witzke, Oliver ;

Wu, Jingyang ;

Sundberg, Aimee K. ;

Fournier, Martha .

CLINICAL INFECTIOUS DISEASES, 2022, 75 (04) :690-701

[2] Evaluation of the Effect of Maribavir on Cardiac Repolarization in Healthy Participants: Thorough QT/QTc Study [J].

Ilic, Katarina ;

Song, Ivy ;

Wu, Jingyang ;

Martin, Patrick .

CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2020, 13 (06) :1260-1270

[3] Maribavir pharmacokinetics and the effects of multiple-dose maribavir on cytochrome P450 (CYP) 1A2, CYP2C9, CYP2C19, CYP 2D6, CYP 3A, N-acetyltransferase-2, and xanthine oxidase activities in healthy adults [J].

Ma, JD ;

Nafziger, AN ;

Villano, SA ;

Gaedigk, A ;

Bertino, JS .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (04) :1130-1135

[4] Maribavir for Preemptive Treatment of Cytomegalovirus Reactivation [J].

Maertens, Johan ;

Cordonnier, Catherine ;

Jaksch, Peter ;

Poire, Xavier ;

Uknis, Marc ;

Wu, Jingyang ;

Wijatyk, Anna ;

Saliba, Faouzi ;

Witzke, Oliver ;

Villano, Stephen .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (12) :1136-1147

[5] Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial [J].

Marty, Francisco M. ;

Ljungman, Per ;

Papanicolaou, Genovefa A. ;

Winston, Drew J. ;

Chemaly, Roy F. ;

Strasfeld, Lynne ;

Young, Jo-Anne H. ;

Rodriguez, Tulio ;

Maertens, Johan ;

Schmitt, Michael ;

Einsele, Hermann ;

Ferrant, Augustin ;

Lipton, Jeffrey H. ;

Villano, Stephen A. ;

Chen, Hongzi ;

Boeckh, Michael .

LANCET INFECTIOUS DISEASES, 2011, 11 (04) :284-292

[6] Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study [J].

Papanicolaou, Genovefa A. ;

Silveira, Fernanda P. ;

Langston, Amelia A. ;

Pereira, Marcus R. ;

Avery, Robin K. ;

Uknis, Marc ;

Wijatyk, Anna ;

Wu, Jingyang ;

Boeckh, Michael ;

Marty, Francisco M. ;

Villano, Stephen .

CLINICAL INFECTIOUS DISEASES, 2019, 68 (08) :1255-1264

[7]

Takeda, 2014, SHIR SUCC COMPL TEND

[8]

Takeda, 2019, TAK COMPL ACQ SHIR B

[9]

Takeda Pharmaceuticals, 2021, LIVTENCITY MAR TABL

[10]

US Food & Drug Administration, 2021, FDA APPR 1 TREATM CO

← 1 2 →